Buscar
Congreso SOLACI
HomeInternational CongressesESC 2013 .

ESC 2013 .

Ver Categoría
Day 1

DECAAF: Pre ablation magnetic resonance in patients with atrial fibrillation is capable of detecting the degree of fibrosis and predicting the success of...

260 patients with atrial fibrillation were included who underwent nuclear magnetic resonance 30 days before ablation and...
solaci -
Ver más
Day 1

PRAGUE 14: Anti-thrombotic therapy before non-cardiac surgery may be associated with a higher incidence of bleeding.

The majority of coronary patients are under anti-thrombotic therapy and its interruption may increase cardiovascular risk, while...
solaci -
Ver más
Day 1

LINC: The LUCAS device failed to demonstrate benefit in cardiac arrest patients.

Each year between 300,000 and 400,000 people suffer an out-of-hospital heart attack in Europe. Only between 5%...
solaci -
Ver más
Day 1

PARIS: Interruption of dual antiplatelet treatment can be safe depending on the clinical context and treatment time

The cessation of dual antiplatelet treatment increased the risk of post coronary intervention adverse events. It is...
solaci -
Ver más
Day 1

PRAMI: Treating other lesions in addition to the culprit of an acute infarction reduces events.

In the context of an ST-segment elevation myocardial infarction, primary angioplasty to treat the culprit lesion improves...
solaci -
Ver más
Day 1

INTIME: Home monitoring of severe heart failure patients gives promising results.

Rehospitalization or death due to worsening heart failure is often preceded by changes in clinical parameters, weight...
solaci -
Ver más
Day 1

Hokusai-VTE: Endoxaban shows solid results versus warfarin in venous thromboembolism .

The venous thromboembolism is the third most common cardiovascular disease after acute myocardial infarction and stroke ....
solaci -
Ver más
Day 3

ATOMIC: Omecamtiv Mecarbil does not relieve dyspnea in patients with heart failure

This is a phase 2 randomized, double-blind controlled study to test the effect of omecamtiv mecarbil on...
solaci -
Ver más

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

TricValve Transcatheter Bicaval Valve System for Severe Tricuspid Insufficiency: Events at One Year

Dr. Omar Tupayachi - 0
TricValve is the first bicaval valve system to obtain CE-Mark approval. This device heterotopic device eliminates tricuspid insufficiency reflux into the venous system, reducing...

Long Term Results of the International Chimney Registry

Dr. Omar Tupayachi - 0
The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

Dr. Omar Tupayachi - 0
The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

Noticias Institucionales

Hemodynamics and Interventional Cardioangiology Hybrid Training Course SOLACI-CACI

solaci - 0
We are now open for registration to the hybrid training course on Hemodynamics and Interventional Cardioangiology for Technicians and Nurses SOLACI-CACI 2025 Find all course...

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad